Literature DB >> 35306542

Feasibility of home-based exercise training in men with metastatic castration-resistant prostate cancer.

Erik D Hanson1,2, Mohamdod Alzer3, Jackson Carver3, Cameron K Stopforth3, Alexander R Lucas4,5, Young E Whang6,7, Matthew I Milowsky6,7, David B Bartlett8,9, Michael R Harrison8, Rhonda L Bitting4, Allison M Deal6, Lee Stoner3, A C Hackney3,10, Claudio L Battaglini3,6.   

Abstract

BACKGROUND: Home-based training increases accessibility to exercise and mitigates the side effects of hormone therapy for prostate cancer (PC). However, it is unknown if men with more advanced disease are willing to partake in such interventions.
PURPOSE: To determine the feasibility of a home-based exercise intervention in men with metastatic castration-resistant prostate cancer (mCRPC).
METHODS: mCRPC patients on androgen receptor signaling inhibitors (ARSI) were prescribed a 12-week, home-based exercise intervention using resistance bands and walking. Feasibility was assessed using recruitment, retention, adherence, and outcome capture. Physiological changes and patient reported outcomes were assessed before and after the intervention.
RESULTS: Of the 62 referrals, 47 were eligible with 22 men performing baseline testing (47% recruitment rate) and 16 completing the intervention (73% retention). Task completion was >86% for all physiological tests. Walking adherence was 80% and resistance training was 63%, the latter falling short of the study target (75%). Training increased thigh muscle cross-sectional area by 22%, time to exhaustion by 19% (both p < 0.05) and peak oxygen uptake by 6% (p = 0.057). Improvements in short physical performance battery scores and 400 m walk demonstrated moderate effect sizes that did not reach significance.
CONCLUSIONS: Home-based exercise is feasible during ARSI treatment for mCRPC. Greater endurance capacity and localized hypertrophy appear as the primary improvements following training. These preliminary findings suggest home-based training may increase exercise accessibility, with important lessons that will inform subsequent trials investigating the efficacy of home-based exercise interventions during mCRPC.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 35306542     DOI: 10.1038/s41391-022-00523-8

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  47 in total

1.  Sarcopenia during androgen-deprivation therapy for prostate cancer.

Authors:  Matthew R Smith; Fred Saad; Blair Egerdie; Paul R Sieber; Teuvo L J Tammela; Chunlei Ke; Benjamin Z Leder; Carsten Goessl
Journal:  J Clin Oncol       Date:  2012-05-29       Impact factor: 44.544

2.  Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.

Authors:  Kim N Chi; Andrew Protheroe; Alfredo Rodríguez-Antolín; Gaetano Facchini; Henrik Suttman; Nobuaki Matsubara; Zhangqun Ye; Bhumsuk Keam; Ronaldo Damião; Tracy Li; Kelly McQuarrie; Bin Jia; Peter De Porre; Jason Martin; Mary B Todd; Karim Fizazi
Journal:  Lancet Oncol       Date:  2018-01-08       Impact factor: 41.316

3.  Physical function changes in prostate cancer patients on androgen deprivation therapy: a 2-year prospective study.

Authors:  Matthew E Levy; Subashan Perera; Gijsberta J van Londen; Joel B Nelson; Cheryl A Clay; Susan L Greenspan
Journal:  Urology       Date:  2008-02-15       Impact factor: 2.649

4.  Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation.

Authors:  D A Galvão; D R Taaffe; N Spry; D Joseph; D Turner; R U Newton
Journal:  Prostate Cancer Prostatic Dis       Date:  2008-10-14       Impact factor: 5.554

5.  Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study.

Authors:  Gijsberta J van Londen; Matthew E Levy; Subashan Perera; Joel B Nelson; Susan L Greenspan
Journal:  Crit Rev Oncol Hematol       Date:  2008-08-15       Impact factor: 6.312

Review 6.  Does androgen-deprivation therapy accelerate the development of frailty in older men with prostate cancer?: a conceptual review.

Authors:  Kathryn Bylow; Supriya G Mohile; Walter M Stadler; William Dale
Journal:  Cancer       Date:  2007-12-15       Impact factor: 6.860

7.  Physical function in men with prostate cancer on androgen deprivation therapy.

Authors:  Cheryl A Clay; Subashan Perera; Julie M Wagner; Megan E Miller; Joel B Nelson; Susan L Greenspan
Journal:  Phys Ther       Date:  2007-08-07

8.  Intervening on the side effects of hormone-dependent cancer treatment: the role of strength training.

Authors:  Erik D Hanson; Ben F Hurley
Journal:  J Aging Res       Date:  2011-01-13

9.  Changes in physical functioning and muscle strength in men receiving androgen deprivation therapy for prostate cancer: a controlled comparison.

Authors:  Brian D Gonzalez; Heather S L Jim; Brent J Small; Steven K Sutton; Mayer N Fishman; Babu Zachariah; Randy V Heysek; Paul B Jacobsen
Journal:  Support Care Cancer       Date:  2015-11-13       Impact factor: 3.359

10.  Reduced Cardiovascular Capacity and Resting Metabolic Rate in Men with Prostate Cancer Undergoing Androgen Deprivation: A Comprehensive Cross-Sectional Investigation.

Authors:  Bradley A Wall; Daniel A Galvão; Naeem Fatehee; Dennis R Taaffe; Nigel Spry; David Joseph; Robert U Newton
Journal:  Adv Urol       Date:  2015-10-26
View more
  1 in total

1.  Home-based exercise for men with mCRPC.

Authors:  Louise Stone
Journal:  Nat Rev Urol       Date:  2022-05       Impact factor: 14.432

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.